Egfr Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Epidermal growth factor receptor (EGFR, also known as HER1 or ErbB1) is a prototype receptor tyrosine kinase that plays fundamental roles in cell growth, proliferation, differentiation, and survival. EGFR is activated by binding of growth factors including EGF, TGF-α, and amphiregulin, leading to receptor dimerization, autophosphorylation, and activation of multiple downstream signaling pathways including RAS/RAF/MEK/ERK, PI3K/AKT, and STAT. In the nervous system, EGFR is expressed in neural stem cells, astrocytes, and neurons, where it regulates neurogenesis, gliogenesis, synaptic plasticity, and neural repair. EGFR signaling is particularly important in neural progenitor cell proliferation and is reactivated following brain injury. Dysregulated EGFR signaling is a hallmark of many cancers and has been implicated in glioblastoma and neurodegenerative diseases.
| EGFR Protein | |
|---|---|
| Protein Name | EGFR Protein |
| Gene | EGFR |
| UniProt ID | P00533 |
| PDB IDs | 1NQL, 2RBP, 4ZJV |
| Molecular Weight | 134.3 kDa |
| Subcellular Location | Plasma membrane |
| Protein Family | ErbB/EGFR tyrosine kinase family |
EGFR Protein is a ErbB/EGFR tyrosine kinase family. This protein contains extracellular ligand-binding domains, a transmembrane helix, and an intracellular tyrosine kinase domain that is activated upon ligand binding and dimerization.
EGFR (Epidermal Growth Factor Receptor) is a receptor tyrosine kinase that binds EGF, TGF-α, and other ligands. It activates multiple signaling pathways including MAPK/ERK, PI3K/AKT, and JAK/STAT. EGFR regulates cell growth, proliferation, differentiation, and survival. In the brain, EGFR is expressed in neurons and astrocytes and regulates synaptic plasticity, neurogenesis, and glial function.
EGFR is one of the most frequently altered oncogenes. Mutations/amplification occur in lung cancer, glioblastoma, colorectal cancer, and others. In AD, EGFR signaling is altered and may contribute to amyloid processing and neuroinflammation. EGFR is a major therapeutic target in oncology.
Many EGFR inhibitors are approved: Gefitinib, Erlotinib, Afatinib, Osimertinib (lung cancer), Cetuximab (colorectal cancer). EGFR antibodies and tyrosine kinase inhibitors are widely used. Potential for neurodegenerative disease treatment is under investigation.
The study of Egfr Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.